HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Taylor-Fishwick, D. A Articles by Vinik, A. I Search for Related Content PubMed PubMed Citation Articles by Taylor-Fishwick, D. A Articles by Vinik, A. I

¹ Departments of Internal Medicine,
² Microbiology and Molecular Cell Biology,
³ Anatomy and Pathology, Eastern Virginia Medical School, 855 W Brambleton Avenue, Norfolk, 23510 Virginia, USA
⁴ NIDDK, NIH, DHHS, Mark O Hatfield Clinical Research Center, Room 5-5940, Bethesda, Maryland 20892, USA

(Requests for offprints should be addressed to D A Taylor-Fishwick, Rm 215 Suite B, Eastern Virginia Medical School, Strelitz Diabetes Research Institute, 855 W Brambleton Avenue, Norfolk, Virginia 23510, USA; Email: taylord{at}evms.edu)

Islet neogenesis associated protein (INGAP) is a protein factor that can stimulate new islet mass from adult pancreatic progenitor cells. In models of islet neogenesis, INGAP expression is elevated in pancreatic acinar cells. Using a transgenic model to drive a sustained expression of INGAP in pancreatic acinar cells, we have identified a protection to chemical-induced hyperglycemia. A sustained expression of INGAP during development did not perturb islet development or basal blood glucose homeostasis, although ß-cell mass and pancreatic insulin content were significantly increased in the INGAP transgenic mice. When challenged with a diabetogenic dose of streptozotocin (STZ), mice carrying the INGAP transgene did not become hyperglycemic. In contrast, wild-type mice became and remained hyperglycemic, blood glucose > 550 mg/dl. The serum insulin levels and islet morphology were preserved in the transgenic mice after STZ treatment. These data suggest that the sustained expression of INGAP in the acinar pancreas confers resistance to a diabetogenic insult. The INGAP transgenic mouse provides a new model to uncover factors that are protective to diabetes onset and biomarkers to track ß-cell pathology.

This article has been cited by other articles:

				D. A. Taylor-Fishwick, A. Bowman, M. Korngiebel-Rosique, and A. I. Vinik Pancreatic Islet Immunoreactivity to the Reg Protein INGAP J. Histochem. Cytochem., February 1, 2008; 56(2): 183 - 191. [Abstract] [Full Text] [PDF]